MedTrace Logo

SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)

NCT02710955 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-11-14

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy of a new thickened formula on regurgitation

Conditions

  • Gastroesophageal Reflux

Interventions

DIETARY_SUPPLEMENT

Thickened infant formula

Sponsors & Collaborators

  • United Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Yvan Vandenplas, MD · Universitair Ziekenhuis Brussel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Week
Max Age
5 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2017-01-21
Completion
2017-04-12

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710955 on ClinicalTrials.gov